{"disease":{"id":"hormone-receptor-hr-positive-low-her2-advanced-breast-cancer-patients-her2-ihc-1-or-2-ish-negative","name":"hormone receptor hr positive low her2 advanced breast cancer patients her2 ihc 1 or 2 ish negative"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06837792","title":"Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":141,"lead_sponsor_name":"Yonsei University","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}